Insmed Incorporated
Insmed Incorporated Fundamental Analysis
Insmed Incorporated (INSM) shows moderate financial fundamentals with a PE ratio of -23.28, profit margin of -2.11%, and ROE of -1.68%. The company generates $0.6B in annual revenue with strong year-over-year growth of 19.17%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -294.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze INSM's fundamental strength across five key dimensions:
Efficiency Score
WeakINSM struggles to generate sufficient returns from assets.
Valuation Score
ModerateINSM shows balanced valuation metrics.
Growth Score
ModerateINSM shows steady but slowing expansion.
Financial Health Score
ModerateINSM shows balanced financial health with some risks.
Profitability Score
WeakINSM struggles to sustain strong margins.
Key Financial Metrics
Is INSM Expensive or Cheap?
P/E Ratio
INSM trades at -23.28 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, INSM's PEG of 6.55 indicates potential overvaluation.
Price to Book
The market values Insmed Incorporated at 40.22 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -25.27 times EBITDA. This is generally considered low.
How Well Does INSM Make Money?
Net Profit Margin
For every $100 in sales, Insmed Incorporated keeps $-2.11 as profit after all expenses.
Operating Margin
Core operations generate -1.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.68 in profit for every $100 of shareholder equity.
ROA
Insmed Incorporated generates $-56.38 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Insmed Incorporated generates limited operating cash flow of $-943.39M, signaling weaker underlying cash strength.
Free Cash Flow
Insmed Incorporated generates weak or negative free cash flow of $-1.01B, restricting financial flexibility.
FCF Per Share
Each share generates $-4.67 in free cash annually.
FCF Yield
INSM converts -3.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-23.28
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
6.55
vs 25 benchmark
P/B Ratio
Price to book value ratio
40.22
vs 25 benchmark
P/S Ratio
Price to sales ratio
49.45
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.83
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.68
vs 25 benchmark
ROA
Return on assets percentage
-0.56
vs 25 benchmark
ROCE
Return on capital employed
-0.66
vs 25 benchmark
How INSM Stacks Against Its Sector Peers
| Metric | INSM Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -23.28 | 28.25 | Better (Cheaper) |
| ROE | -168.36% | 780.00% | Weak |
| Net Margin | -210.54% | -20122.00% (disorted) | Weak |
| Debt/Equity | 1.04 | 0.30 | Weak (High Leverage) |
| Current Ratio | 3.83 | 4.66 | Strong Liquidity |
| ROA | -56.38% | -14687.00% (disorted) | Weak |
INSM outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Insmed Incorporated's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
37.38%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-85.20%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-40.64%
Industry Style: Defensive, Growth, Innovation
Declining